Page 52 - Read Online
P. 52

Hall et al. Hepatoma Res. 2026;12:20                                             Page 13 of 15





               Copyright
               © The Author(s) 2026.


               REFERENCES

               0.  REFERENCES .
               1.  Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36
                  cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63. DOI
               2.  Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular
                  carcinoma. Hepatology. 2023;78:1922-65. DOI PubMed PMC
               3.  Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol.
                  2018;69:182-236. DOI
               4.  Brown AM, Kassab I, Massani M, et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient
                  level meta analysis. Cancer Medicine. 2022;12:2590-9. DOI PubMed PMC
               5.  Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional therapy approaches for hepatocellular carcinoma: recent
                  advances and management strategies. Cancers. 2020;12:1914. DOI PubMed PMC
               6.  Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.
                  World J Gastroenterol. 2021;27:7462-79. DOI PubMed PMC
               7.  Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres
                  compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled
                  phase 3 trial. Lancet Oncol. 2017;18:1624-36. DOI PubMed
               8.  Lee YB, Nam JY, Cho EJ, et al. A Phase I/IIa Trial of Yttrium-90 radioembolization in combination with durvalumab for locally
                  advanced unresectable hepatocellular carcinoma. Clin Cancer Res. 2023;29:3650-8. DOI
               9.  Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J
                  Gastroenterol. 2023;29:1054-75. DOI PubMed PMC
               10.  Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol.
                  2022;76:681-93. DOI PubMed PMC
               11.  Teo J, Goh BK. Contra-lateral liver lobe hypertrophy after unilobar Y90 radioembolization: an alternative to portal vein embolization?
                  World J Gastroenterol. 2015;21:3170-3. DOI PubMed PMC
               12.  Molvar C, Lewandowski R. Yttrium-90 radioembolization of hepatocellular carcinoma-performance, technical advances, and future
                  concepts. Semin intervent Radiol. 2015;32:388-97. DOI
               13.  Lewandowski R, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin intervent
                  Radiol. 2006;23:064-72. DOI PubMed PMC
               14.  Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J
                  Radiat Oncol Biol Phys. 2011;79:163-71. DOI
               15.  Busse NC, Al‐ghazi MSAL, Abi‐Jaoudeh N, et al. AAPm medical physics practice guideline 14.a: yttrium-90 microsphere
                  radioembolization. J Appl Clin Med Phys. 2023;25:e14157. DOI PubMed PMC
               16.  Boas FE, Bodei L, Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med.
                  2017;58 Suppl:104S-11S. DOI PubMed PMC
               17.  Wagemans ME, Kunnen B, Stella M, et al. Comparison of 3 different therapeutic particles in radioembolization of locally advanced
                  intrahepatic cholangiocarcinoma. J Nucl Med. 2024;65:272-8. DOI
               18.  Villalobos A, Arndt L, Cheng B, et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the
                  effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres. J Vasc Interv Radiol. 2023;34:1226-34. DOI
               19.  Gulec SA, Mcgoron AJ. Radiomicrosphere dosimetry: principles and current state of the art. Semin Nucl Med. 2022;52:215-28. DOI
               20.  Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial radioembolization dosimetry in 2022. Cardiovasc Intervent Radiol.
                  2022;45:1608-21. DOI
               21.  Feely M, Tondon R, Gubbiotti M, et al. Gastrointestinal tract injury by yttrium-90 appears largely restricted to resin microspheres but
                  can occur years after embolization. Am J Surg Pathol. 2022;46:1234-40. DOI
               22.  Kis B, Gyano M. Radiation pneumonitis after yttrium-90 radioembolization: a systematic review. J Vasc Interv Radiol. 2025;36:207-18.
                  DOI
               23.  Hickey RM, Lewandowski RJ, Salem R. Yttrium-90 radioembolization for hepatocellular carcinoma. Semin Nucl Med. 2016;46:105-8.
                  DOI
   47   48   49   50   51   52   53   54   55   56   57